Reporter Gene News and Research

RSS

New 'reporter viruses' make it easier to observe SARS-CoV-2 in real time

A version of SARS-CoV-2, the virus that causes COVID-19 disease, has been successfully modified to glow brightly in cells and animal tissues, providing a real-time way to track the spread and intensity of viral infection as it happens in animal models, researchers at Texas Biomedical Research Institute report in the journal The Proceedings of the National Academy of Sciences.

27 Sep 2021

Heidelberg researchers focus on developing drugs against flavi- and coronaviruses

New drugs are intended to help stop viral zoonoses - infections that jump from animals to humans. To study suitable inhibitors, Prof. Dr Christian Klein from the Institute of Pharmacy and Molecular Biotechnology of Heidelberg University is receiving funding in the amount of 450,000 euros from the Volkswagen Foundation.

20 Aug 2021

A path to treat currently untreatable cases of cystic fibrosis is clearly achievable, study suggests

An experimental drug reported in Nature Communications suggests that a "path is clearly achievable" to treat currently untreatable cases of cystic fibrosis disease caused by nonsense mutations.

19 Jul 2021

Researchers demonstrate a potentially powerful strategy for treating cystic fibrosis

UNC School of Medicine scientists led a collaboration of researchers to demonstrate a potentially powerful new strategy for treating cystic fibrosis (CF) and potentially a wide range of other diseases.

16 Jun 2021

Neanderthal-derived genetic locus influences COVID-19 severity in humans

Researchers in the United States and Estonia have identified four genetic variants on a chromosome 3 haplotype that may be responsible for driving the association between this locus and the severity of coronavirus disease 2019 (COVID-19).

15 Jun 2021

Researchers identify kite-shaped molecules that block SARS-CoV-2 cell entry after attachment

They have identified a group of kite-shaped compounds that are highly specific to SARS-CoV-1 and SARS-CoV-2. These compounds demonstrate high potency in inhibiting SARS-CoV-2 infection at early entry steps. The study is currently available on the bioRxiv* preprint server.

2 Jun 2021

Research suggests Garcinia kola extract might suppress severe COVID-19 cytokine storms

Researchers in the UK and Nigeria have conducted a study showing that Garcinia kola seed extract and garcinoic acid may provide therapeutic benefits in the late stage of severe coronavirus disease 2019 (COVID-19) and other coronavirus infections.

24 May 2021

New study will help investigate innate immune responses to viral infections

Researchers from Boston University School of Medicine (BUSM) report the formation of human cells containing a green fluorescent protein or GFP (one of the most important proteins in biology and fluorescence imaging) genetically fused with two interferon stimulated genes (ISGs), namely Viperin and ISG15.

19 May 2021

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

Researchers in the United States have developed an alternative messenger RNA (mRNA) delivery platform to the lipid nanoparticles that are currently used in vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

18 Apr 2021

Advancing the Diagnosis and Treatment of Ovarian Cancer

In this interview, News-Medical talks to Dr. Marcos Quintela Vasquez about the work he is conducting regarding the diagnosis and treatment of ovarian cancer in partnership with Porvair Sciences.

From Porvair Sciences Limited 7 Apr 2021

New study maps SARS-CoV-2 and host protein interactions in detail

A new study has developed a systemic map detailing the mechanistic interactions and disruptions between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its host cell.

18 Mar 2021

SARS-CoV-2 proteins are potent suppressors of innate immunity

A new study describes the strong immune-suppressing activity of SARS-CoV-2 genes, among other coronavirus genes.

5 Mar 2021

Unique nanoparticles can package and deliver gene-editing machinery to the liver

The genome editing technology CRISPR has emerged as a powerful new tool that can change the way we treat disease. The challenge when altering the genetics of our cells, however, is how to do it safely, effectively, and specifically targeted to the gene, tissue and organ that needs treatment.

2 Mar 2021

Scientists successfully restore circadian function in the liver of arrhythmic mice

Circadian clocks, which regulate the metabolic functions of all living beings over a period of about 24 hours, are one of the most fundamental biological mechanisms.

18 Feb 2021

Amilorides reduce SARS-CoV-2 viral replication in vitro

A new U.S. study published on the bioRxiv preprint server reports the use of an amiloride-based scaffold that targets a viral RNA structure known to be essential in viral replication in the 5’-untranslated region (UTR) of the virus. The researchers say this heralds the application of these molecules as chemical probes to explore viral biology and produce specific antivirals targeting RNA regions of the coronavirus genome.

8 Dec 2020

Researchers develop recombinant SARS-CoV-2 model to aid vaccine and antiviral research

Researchers have developed a fluorescent reporter gene-bearing recombinant form of SARS-CoV-2, which is capable of replication.

23 Nov 2020

Study shows brilacidin strongly inhibits SARS-CoV-2 in laboratory cell lines

A recent study by US researchers reveals that brilacidin, a small synthetic molecule with peptide-like properties, exerts potent in vitro antiviral activity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – both as a standalone treatment and in combination with FDA-approved remdesivir. The study is currently available on the bioRxiv preprint server.

4 Nov 2020

Synthetic riboregulators detect SARS-CoV-2 genome parts in 40 minutes

By exploiting the tools of synthetic biology, the researchers from Turkey have successfully developed a de novo riboregulator system for rapidly detecting the presence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomic material. Their paper is currently available on medRxiv preprint server.

2 Aug 2020

A biomaterial vaccine for SARS-CoV-2 - quick and scalable

A recent 'tour-de-force' research endeavor, led by scientists from Harvard University, explored the propensity of a biomaterial vaccine based on mesoporous silica rods to spawn highly protective humoral responses against relevant antigens of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Jul 2020

Study shows human monoclonal antibodies can effectively neutralize SARS-CoV-2

US researchers have published a proof of concept on the efficacy of human monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in laboratory conditions, as well as their pioneering use in a mouse model. The study is available on the preprint server bioRxiv*.

17 May 2020